Figure 4. Theranostic LbL NP biodistribution in a metastatic model of ovarian cancer indicates tumor targeting capabilities, especially using intraperitoneal (IP) administration.

(a) A metastatic model of ovarian cancer was used to evaluate whether IP-administration of nanoparticles improved biodistribution and sensistivity of the diagnostic function of the theranostic NPs. (b) NP accumulation in liver, spleen, and tumors was measured 72 hours post-administration using a fluorescent flatbed scanner (Li-COR Odyssey). Tissue autofluorescence was used to generate a region-of-interest (indicated by the white outline) in which to quantify signal from the Cy7-labeled NPs (Figure S6). (c) Urine was collected 1-hour post-IP administration of NP+SR and analyzed for the MMP9-sensitive biomarker. (d–f) Cryohistology was performed on tumor tissue and imaged using a fluorescent slide scanner to detect tissue autofluorescence (pseudo-colored magenta) and NP signal (pseudo-colored green). These representative images of LbL NP distribution through tumors when administered (d–e) IP and (f) intravenously. Scale bar = 100 μm. Error bars represent SEM, and statistical analysis was carried out using an unpaired student’s t-test.